NO20071341L - Stabilt, pegylert interferonpreparat. - Google Patents
Stabilt, pegylert interferonpreparat.Info
- Publication number
- NO20071341L NO20071341L NO20071341A NO20071341A NO20071341L NO 20071341 L NO20071341 L NO 20071341L NO 20071341 A NO20071341 A NO 20071341A NO 20071341 A NO20071341 A NO 20071341A NO 20071341 L NO20071341 L NO 20071341L
- Authority
- NO
- Norway
- Prior art keywords
- pegylated interferon
- formulations
- stable
- interferon preparation
- preparation
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 3
- 108010050904 Interferons Proteins 0.000 title abstract 3
- 229940079322 interferon Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60084604P | 2004-08-12 | 2004-08-12 | |
| PCT/US2005/028441 WO2006020720A2 (en) | 2004-08-12 | 2005-08-11 | Stable pegylated interferon formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071341L true NO20071341L (no) | 2007-03-12 |
Family
ID=35885766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071341A NO20071341L (no) | 2004-08-12 | 2007-03-12 | Stabilt, pegylert interferonpreparat. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7632491B2 (de) |
| EP (1) | EP1796647B1 (de) |
| JP (1) | JP4971160B2 (de) |
| KR (1) | KR20070045244A (de) |
| CN (1) | CN101039660B (de) |
| AT (1) | ATE476967T1 (de) |
| AU (1) | AU2005272862B2 (de) |
| BR (1) | BRPI0513332A (de) |
| CA (1) | CA2576549C (de) |
| DE (1) | DE602005022895D1 (de) |
| ES (1) | ES2349472T3 (de) |
| MX (1) | MX2007001663A (de) |
| NO (1) | NO20071341L (de) |
| WO (1) | WO2006020720A2 (de) |
| ZA (1) | ZA200701154B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4463814B2 (ja) | 2003-08-05 | 2010-05-19 | ノボ ノルディスク アクティーゼルスカブ | 新規のインスリン誘導体 |
| EP1969004B1 (de) | 2005-12-28 | 2011-08-10 | Novo Nordisk A/S | Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen |
| PT2097068E (pt) * | 2006-11-24 | 2013-10-23 | Cadila Healthcare Ltd | Formulações de conjugados de peg-interferão alfa |
| EP2117514B1 (de) * | 2007-03-05 | 2011-06-15 | Cadila Healthcare Limited | Zusammensetzungen mit peg-interferon-alpha-konjugaten und raffinose als kryoschutzmittel |
| US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| PL2234645T3 (pl) * | 2007-12-20 | 2012-10-31 | Merck Serono Sa | Preparaty interferonu-beta modyfikowanego PEG |
| US9884019B2 (en) * | 2008-08-05 | 2018-02-06 | Wyeth Llc | Lyophilization above collapse |
| ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| WO2010064258A2 (en) * | 2008-12-01 | 2010-06-10 | Intas Biopharmaceuticals Limited | Pharmaceutical formulations of interferon conjugates |
| DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
| WO2012118687A1 (en) * | 2011-02-28 | 2012-09-07 | Merck Sharp & Dohme Corp. | Manually operated injector with restricted injection sequence |
| LT2701720T (lt) | 2011-04-28 | 2017-11-10 | Oncopeptides Ab | Liofilizuotas citotoksinių dipeptidų preparatas |
| KR20150074167A (ko) * | 2012-10-26 | 2015-07-01 | 루핀 리미티드 | Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물 |
| US20140199286A1 (en) * | 2013-01-15 | 2014-07-17 | Teva Pharmaceutical Industries, Ltd. | Lyophilization process |
| CN103054818B (zh) * | 2013-01-28 | 2014-03-05 | 苏州二叶制药有限公司 | 一种优质高效的冷冻干燥技术 |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
| CN108379561B (zh) * | 2018-03-01 | 2021-11-26 | 修正生物医药（杭州）研究院有限公司 | 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR102562968B1 (ko) * | 2018-11-01 | 2023-08-04 | 주식회사 셀비온 | 붕소 중성자 포획 치료용 파라-보로노페닐알라닌 조성물 및 이의 제조방법 |
| JP7518149B2 (ja) | 2019-07-12 | 2024-07-17 | ノヴォ ノルディスク アー／エス | 高濃度インスリン製剤 |
| CN112245570A (zh) * | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| CN112807281A (zh) * | 2019-10-31 | 2021-05-18 | 南京海维医药科技有限公司 | 包含血管紧张素ii的稳定组合物及其制备方法、使用方法 |
| CN116157138A (zh) * | 2020-09-11 | 2023-05-23 | 联邦高等教育系统匹兹堡大学 | 源自细胞外基质的最终灭菌的水凝胶或胶体悬浮液的制备方法及其用途 |
| CN113797318B (zh) * | 2021-10-26 | 2023-06-30 | 深圳科兴药业有限公司 | 一种干扰素组合物及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3262575D1 (en) * | 1981-12-23 | 1985-04-18 | Schering Corp | Stabilised interferon formulations and their preparation |
| CA2024046A1 (en) | 1989-09-28 | 1991-03-29 | Alberto Ferro | Stabilized leukocyte-interferons |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| NZ276943A (en) | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5691298A (en) * | 1994-12-14 | 1997-11-25 | The Procter & Gamble Company | Ester oligomers suitable as soil release agents in detergent compositions |
| DE69620877T2 (de) | 1995-02-06 | 2002-12-12 | Genetics Institute, Inc. | Arzneimittelformulierungen für il-12 |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6180096B1 (en) * | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| BR9909087A (pt) * | 1998-03-26 | 2000-12-05 | Schering Corp | Formulações para proteção de conjugados peg-alfa interferon |
| HUP0202525A3 (en) * | 1999-08-13 | 2003-11-28 | Hoffmann La Roche | Mycophenolate mofetil in association with peg-ifn-alpha, medicaments and kit comprising thereof |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| WO2003049760A1 (en) | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
-
2005
- 2005-08-11 MX MX2007001663A patent/MX2007001663A/es active IP Right Grant
- 2005-08-11 CA CA2576549A patent/CA2576549C/en not_active Expired - Fee Related
- 2005-08-11 KR KR1020077003190A patent/KR20070045244A/ko not_active Withdrawn
- 2005-08-11 ES ES05785190T patent/ES2349472T3/es not_active Expired - Lifetime
- 2005-08-11 AT AT05785190T patent/ATE476967T1/de not_active IP Right Cessation
- 2005-08-11 EP EP05785190A patent/EP1796647B1/de not_active Expired - Lifetime
- 2005-08-11 BR BRPI0513332-7A patent/BRPI0513332A/pt not_active IP Right Cessation
- 2005-08-11 US US11/201,731 patent/US7632491B2/en active Active
- 2005-08-11 AU AU2005272862A patent/AU2005272862B2/en not_active Ceased
- 2005-08-11 WO PCT/US2005/028441 patent/WO2006020720A2/en not_active Ceased
- 2005-08-11 JP JP2007525768A patent/JP4971160B2/ja not_active Expired - Fee Related
- 2005-08-11 CN CN2005800348502A patent/CN101039660B/zh not_active Expired - Fee Related
- 2005-08-11 DE DE602005022895T patent/DE602005022895D1/de not_active Expired - Lifetime
-
2007
- 2007-02-08 ZA ZA200701154A patent/ZA200701154B/xx unknown
- 2007-03-12 NO NO20071341A patent/NO20071341L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005272862B2 (en) | 2011-03-10 |
| ZA200701154B (en) | 2008-08-27 |
| JP4971160B2 (ja) | 2012-07-11 |
| CA2576549C (en) | 2011-01-18 |
| BRPI0513332A (pt) | 2008-05-06 |
| CA2576549A1 (en) | 2006-02-23 |
| WO2006020720A3 (en) | 2006-06-01 |
| US7632491B2 (en) | 2009-12-15 |
| CN101039660B (zh) | 2010-10-06 |
| DE602005022895D1 (de) | 2010-09-23 |
| MX2007001663A (es) | 2007-04-10 |
| CN101039660A (zh) | 2007-09-19 |
| EP1796647B1 (de) | 2010-08-11 |
| ATE476967T1 (de) | 2010-08-15 |
| US20060051320A1 (en) | 2006-03-09 |
| AU2005272862A1 (en) | 2006-02-23 |
| EP1796647A2 (de) | 2007-06-20 |
| WO2006020720A2 (en) | 2006-02-23 |
| ES2349472T3 (es) | 2011-01-03 |
| JP2008509919A (ja) | 2008-04-03 |
| HK1103977A1 (en) | 2008-01-04 |
| KR20070045244A (ko) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071341L (no) | Stabilt, pegylert interferonpreparat. | |
| DK1791532T3 (da) | Sammensætning i mikropelletform med styret afgivelse af fysiologisk aktive stoffer, fremgangsmåde til deres fremstilling og anvendelse i den zootekniske sektor | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| EA200701065A1 (ru) | Инъецируемые составы, содержащие нанодисперсный оланзапин | |
| MX2007010771A (es) | Anfifilos peptidicos para union a heparina angiogenicos. | |
| EA201170703A1 (ru) | Производные адамантилбензамида | |
| DK2336329T3 (da) | Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer | |
| BRPI0409133A (pt) | formulações farmacêuticas contendo metilnaltrexona | |
| MX2007005156A (es) | Trehalosa y/o isomaltulosa como excipiente para formulaciones de aroma secas. | |
| IN2015DN03936A (de) | ||
| WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
| WO2009137778A3 (en) | Methods and compositions for genetically engineering clostridia species | |
| TW200614987A (en) | Novel compounds | |
| WO2010127142A3 (en) | Use of lignosulfonates in suspo-emulsions for producing pesticide compositions | |
| ZA200703274B (en) | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens | |
| ZA200905690B (en) | Compositions comprising peg-interferon alpha conjugates and raffinose as cryoprotectant | |
| WO2006069719A3 (en) | Lyophilization of virosomes | |
| MY153391A (en) | Composition for controlling parasites on animals | |
| WO2005048731A3 (en) | Lecithin-containing granular compositions and methods of their preparation | |
| TW200630118A (en) | Stabilized freeze-dried formulation for cephalosporin derivatives | |
| CY1115938T1 (el) | Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin) | |
| WO2006060728A3 (en) | Methods and compositions involving lcrv proteins | |
| WO2006060309A3 (en) | Compositions and methods for ex vivo preservations of organs | |
| ATE503491T1 (de) | Verbesserte anthraximpfstoffe und abgabeverfahren | |
| EP1828305A4 (de) | Dämpfungsarme prepregs, zu ihrer herstellung verwendbare zusammensetzungen und verwendungen dafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |